£40.0M
The financing round was co-led by Radical Ventures and Sofinnova Partners to accelerate the development of programmable biology tools.
"Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job. That’s where Latent Labs comes in. We push the frontiers of generative biology, giving our partners instant access to tools that accelerate their drug design programs."
